

**Name of the Issue: Medplus Health Services Limited**

**1 Type of Issue** Initial Public Offer

**2 Issue Size (Rs. Mn)** 13,982.95\*

\*Source: Prospectus dated December 16, 2021

**3 Grade of issue along with name of the rating agency**

**Name** NA  
**Grade** NA

**4 Subscription Level (Number of times)** 37.52\*

\* excluding Anchor Investor Portion and including Eligible Employees and after technical rejections

Source: Minutes for basis of allotment dated December 20, 2021

**5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%age
(i) On Allotment **	7.34%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2021)	31.14%
(iii) at the end of 1st FY (March 31, 2022)	32.21%
(iv) at the end of 2nd FY (March 31, 2023)	32.65%
(v) at the end of 3rd FY (March 31, 2024) *	Not Available

\*\*Basis of Allotment (excluding pre-issue QIB holding)

\* QIB Holding not disclosed as reporting for relevant period has not been completed.

**6 Financials of the issuer**

Parameters	(Rs. Millions)		
	1st FY (March 31,2022)	2nd FY (March 31,2023)	3rd FY (March 31,2024)*
Income from operations	37,792.79	45,575.76	Not Available
Net Profit/(Loss) for the period	947.16	501.05	Not Available
Paid-up equity share capital	238.60	238.61	Not Available
Reserves excluding revaluation reserves	13,939.12	14,673.17	Not Available

\* Financials not available as reporting for the relevant years has not been completed.

## 7 Trading Status

The equity shares of Medplus Health Services Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

<b>Particulars</b>	<b>Status</b>
(i) at the end of 1st FY (March 31, 2022)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available

\* Trading status not disclosed as the relevant fiscal years have not been completed.

## 8 Change in Directors of Issuer from the disclosures in the offer document

<b>Particulars</b>	<b>Name of Director</b>	<b>Appointed / Resigned</b>
(i) at the end of 1st FY (March 31, 2022)	No Change	No Change
(ii) at the end of 2nd FY (March 31, 2023)	No Change	No Change
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available	Not Available

\* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

## 9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

**10 Status of utilization of issue proceeds**
*(i) As disclosed in the offer document*
*(Rs. Million)*

Particulars	Amount which will be financed from Net Proceeds	Estimated Depoyment		
		Fiscal 2022	Fiscal 2023	Fiscal 2024
Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival	4,671.70	1,239.19	1,586.87	1,845.64
General corporate purposes	1,055.71	500.00	555.71	-
<b>Total</b>	<b>5,727.41</b>	<b>1,739.19</b>	<b>2,142.58</b>	<b>1,845.64</b>

*(ii) Actual utilization*
*(Rs. Million)*

Particulars	Amount which will be financed from Net Proceeds	Actual Utilisation of Net Proceeds as on December 31, 2023	Pending Utilisation*
Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival	4,671.70	4,671.70	-
General corporate purposes	1,111.03	448.53	662.50
<b>Total</b>	<b>5,782.73</b>	<b>5,120.23</b>	<b>662.50</b>

\* The unutilized proceeds of Rs. 662.50 million have been placed as fixed deposits with bank

Source: Stock Exchange Filings

*(iii) Reasons for deviation, if any*

Not applicable

**11 Comments of monitoring agency, if applicable**

(i) Comments on use of funds

Not applicable

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document

Not applicable

(iii) Any other reservations expressed by the monitoring agency about the end use of funds

Not applicable

## 12 Pricing Data

Designated Stock Exchange BSE  
 Issue Price (Rs.) 796\*  
 Listing Date 23-Dec-21

\*The Offer price for Eligible Employees was finalized at Rs. 718 per Equity Share (after considering a discount of Rs. 78 per Equity Share to the Offer Price)

Price parameters	At close of listing day	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March,2022)		
				Closing price	High	Low
Market Price	1,120.85	1,219.65	979.55	1,010.25	1,343.00	921.00
Sensex*	57,315.28	59,037.18	57,989.30	49,509.15	52,516.76	27,500.79
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2023)			As at the end of the 3rd FY after the listing of the issue (31st March,2024) <sup>(1)</sup>		
	Closing price	High	Low	Closing price	High	Low
Market Price	651.15	1,047.00	570.00	Not Available	Not Available	Not Available
Sensex*	58,991.52	63,583.07	50,921.22	Not Available	Not Available	Not Available

\* Being index of BSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

## 13 Basis for Issue Price

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2022)	At the end of 1st FY (March 31,2023)	At the end of 1st FY (March 31,2024)**	
EPS (Basic)	<b>Company</b>					
	Consolidated	2	5.99	8.55	4.17	Not Available
	<b>Peer Group:</b>		<b>Not Applicable</b>			
	<b>Industry Avg</b>		<b>Not Applicable</b>			
P/E	<b>Company</b>					
	Consolidated	2	132.89	118.16	156.15	Not Available
	<b>Peer Group:</b>		<b>Not Applicable</b>			
	<b>Industry Avg</b>		<b>Not Applicable</b>			
RoNW	<b>Company</b>					
	Consolidated	2	8.74%	6.68%	3.36%	Not Available
	<b>Peer Group:</b>		<b>Not Applicable</b>			
	<b>Industry Avg</b>		<b>Not Applicable</b>			

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2022)	At the end of 1st FY (March 31,2023)	At the end of 1st FY (March 31,2024)**	
	<b>Company</b>					
NAV per share	<i>Consolidated</i>	2	65.37	118.84	124.99	Not Available
	<b>Peer Group:</b>					
	<i>Industry Avg</i>			<b>Not Applicable</b>	<b>Not Applicable</b>	

*Notes*

\* Sourced from Prospectus dated December 16, 2021.

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

Company does not have any listed peer

#### 14 Any other material information

Particulars	Date	Remarks
The Board of Directors of our Company, approved the Scheme of Amalgamation ("Scheme") under Section 230 to Section 232 and other relevant provisions of the Companies Act, 2013 for amalgamation between MedPlus Health Services Limited ('Transferee Company') and MHS Pharmaceuticals Private Limited ('Transferor Company'), subject to requisite approvals. The Transferor Company is the wholly owned subsidiary of the Transferee Company.	10-Jan-23	None
The Company has incorporated a wholly-owned subsidiary namely, 'MedPlus Insurance Brokers Private Limited'. As per the Certificate of Incorporation dated 14th July 2022 issued by the Registrar of Companies, Ministry of Corporate Affairs, the date of incorporation of wholly-owned subsidiary is 14th July, 2022.	15-Jul-22	None

Source: Stock Exchange websites i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)